Discover the latest FDA guidance on gene therapy for neurodegenerative diseases, including critical quality attributes, purity evaluation, and early engagement strategies.
Realizing the promise of gene therapy for neurodegenerative disease
Introduction
In a groundbreaking move for the life sciences sector, FDA released long-awaited guidance on gene therapy products in its recently published new guidance for industry.
Introduction: Neurodegenerative diseases encompass a wide array of conditions that are all hallmarked by the slow deterioration of the nervous system.
The guideline not only tackles the progression of gene therapy products for these severe conditions but also sets a path for fresh beginnings in medical science.
Key points to consider from an FDA perspective, based on recent guidance
Characterization of Gene Therapy Products for Neurodegenerative Diseases:
Regulatory Points to Consider:
The FDA guidance does recognize that the CMC considerations related to gene therapy for neurodegenerative diseases are similar to those applicable in other gene therapies. Nevertheless, it does highlight the importance of accounting for specific considerations such as administration routes, product volumes and delivery devices depending on the study population size.
CQAs (critical quality attributes)
FDA describes the significant importance of these and suggests that sponsors should address them across clinical development. This is important in view of the limited sample sizes typical in neurodegenerative disease trials and should allow testing of CQAs early on to ensure that confidence grows about potential effectiveness along with safety.
Purity and Impurity Evaluation:
The evaluation of purity must contain those associated with the product, such as incomplete viral particles and cell subtypes, along with contaminants from the process, i.e., host cell proteins (HCP), host cell DNA, and endotoxin. In order to facilitate cancer researchers, the guidance advocates making and validating assays for discovery of those impurities so that they can be done early in drug development.
If you want to evaluate the functional activity and consistency of gene therapy products, then it is potency assays that are in the spotlight. In cases of neurodegenerative disease studies where a product exhibits multiple modes of action, this is important for assessing different properties of the product. Potency tests must be well-characterized for accuracy and precision before moving on to clinical trials where stricter proof of effectiveness is necessary.
Product Strength:
An evaluation of how well the product meets certain quality requirements, especially for gene therapies intended to be viable for long periods. Before beginning clinical studies, testing for product strength must include an assay that is precise.
Manufacturing Process Changes:
Evaluation by the sponsor as to what effects its manufacturing process changes will have on CQAs is recommended. This includes a risk analysis and, if it is shown to be necessary, a sample retention in accordance with the guidelines for comparability studies. You should always communicate with the FDA openly about any changes to manufacturing.
Device compatibility with delivery:
Whether the gene therapy product is being delivered through devices, the compatibility with these devices is incredibly important. This evaluation includes how the product behaves as it flows through that delivery device, replicating the conditions of a study in humans.
Preclinical Data Early Engagement with FDA:
he guidance strongly supports early engagement with the “FDA, beginning as early as pre-investigational new drug application (pre-IND) meetings. This engagement encourages early conversations on quality pharmaceutical development plans, thus reducing the probability of manufacturing changes causing delays.
Conclusion
Gene therapy products for neurodegenerative diseases are a boon to patients as well as life sciences industry.Introduction of FDA guidance in 2018 Functional assays that measure CQAs, as well as studies of purity and potency, product strength, engagement with the FDA and transparency are essential for sponsors to navigate the gene therapy advancements in neurodegenerative diseases.
As human gene therapy continues to move forward under these promising circumstances, we are hopeful that collaboration and compliance with these guidelines will help us to realize the potential of gene therapeutic interventions in these devastating diseases.
Reach out to BioBoston Consulting to find about our services!
